Oppenheimer Maintains HCA Healthcare(HCA.US) With Buy Rating, Raises Target Price to $400

奧本海默控股維持HCA醫療(HCA.US)買入評級，上調目標價至400美元

moomoo資訊 · 2024/10/28 21:34 · 評級/大行評級

Oppenheimer analyst Michael Wiederhorn maintains $HCA Healthcare (HCA.US)$ with a buy rating, and adjusts the target price from $390 to $400.

According to TipRanks data, the analyst has a success rate of 66.1% and a total average return of 16.2% over the past year.

AnalystRecentRatingAutoNews_206673_20241028_959554caf4db67f7343557c6b6f0bde50946a21e_1730161816632566_mm_en

Furthermore, according to the comprehensive report, the opinions of $HCA Healthcare (HCA.US)$'s main analysts recently are as follows:

The forecast for HCA Healthcare was adjusted with expectations of financial figures falling short of the market consensus, reversing a trend of surpassing projections. This adjustment comes in the wake of disturbances attributed to hurricanes. Despite the recent decline in stock value, there is an anticipation of a potential phase of stabilization.
Despite the challenges posed by the recent hurricanes, HCA Healthcare's Q3 results managed to surpass these adversities. It is anticipated that these effects will persist into Q4, influencing FY2024 guidance towards the lower spectrum. Nevertheless, the company's management forecasts that earnings growth for 2025 will meet or exceed their long-term objectives, supported by an admissions growth trajectory that is projected to exceed the norm by 3%-4%.
After the release of 3Q24 results, expectations from investors were high, yet HCA Healthcare's underlying performance remained strong with same-store revenues increasing by 7.1%, compared to the 7.9% comparative period in the previous year.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

奧本海默控股分析師Michael Wiederhorn維持$HCA醫療 (HCA.US)$買入評級，並將目標價從390美元上調至400美元。

根據TipRanks數據顯示，該分析師近一年總勝率為66.1%，總平均回報率為16.2%。

AnalystRecentRatingAutoNews_206673_20241028_959554caf4db67f7343557c6b6f0bde50946a21e_1730161816632566_mm_tc

此外，綜合報道，$HCA醫療 (HCA.US)$近期主要分析師觀點如下：

對HCA Healthcare的預測進行了調整，預計財務數據將低於市場共識，扭轉了超出預期的趨勢。這種調整是在颶風引起的干擾之後進行的。儘管最近股票價值下跌，但預計可能進入穩定階段。
儘管最近的颶風帶來了挑戰，但HCA Healthcare的第三季度業績還是成功克服了這些逆境。預計這些影響將持續到第四季度，從而影響 FY2024 對較低頻譜的指導。儘管如此，該公司的管理層預測，2025年的收益增長將達到或超過其長期目標，這得益於招生增長軌跡，預計將超過正常水平3％-4％。
在公佈24年第三季度業績後，投資者的期望很高，但HCA Healthcare的基本表現仍然強勁，同店收入增長了7.1％，而去年同期爲7.9％。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

Oppenheimer Maintains HCA Healthcare(HCA.US) With Buy Rating, Raises Target Price to $400

Oppenheimer Maintains HCA Healthcare(HCA.US) With Buy Rating, Raises Target Price to $400

風險及免責聲明

聲明